Profil
Chris Riley currently works at Andelyn Biosciences, Inc., as Director from 2022.
Aktive Positionen von Chris Riley
Unternehmen | Position | Beginn |
---|---|---|
Andelyn Biosciences
Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Direktor/Vorstandsmitglied | 01.01.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Andelyn Biosciences
Andelyn Biosciences BiotechnologyHealth Technology Andelyn Biosciences is a full-service cell and gene therapy company that specializes in the development, characterization, and production of viral vectors for gene therapy. The private company is based in Columbus, OH. The company operates out of three facilities in Ohio and offers support to its clients in developing curative cell and gene therapies from concept through plasmid development and manufacturing, process development, and cgmp clinical and commercial manufacturing. Andelyn's advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of its clients' innovative cell and gene therapies. The company has more than 20 years of experience and has produced cgmp material for over 450 clinical batches and 75 clinical trials. Andelyn's versatile capabilities include cgmp manufacturing capacity for both adherent and suspension processes up to a 2,000-liter capacity. The CEO of the company is Wade Macedone. | Health Technology |